(R)-8-{4-[3-(5-Fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one

ID: ALA196514

Chembl Id: CHEMBL196514

Cas Number: 327026-93-7

PubChem CID: 9954003

Max Phase: Preclinical

Molecular Formula: C24H27FN4O2

Molecular Weight: 422.50

Molecule Type: Small molecule

Names and Identifiers

Synonyms: SLV-314 | Lensiprazine|327026-93-7|Lensiprazine [INN]|SLV-314|UNII-N47MW76OGX|N47MW76OGX|CHEMBL196514|(2R)-8-[4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazin-1-yl]-2-methyl-4H-1,4-benzoxazin-3-one|(R)-8-(4-(3-(5-fluoro-1H-indol-3-yl)propyl)piperazin-1-yl)-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one|LENSIPRAZINE [WHO-DD]|DTXSID60186379|BDBM50176019|AKOS040752471|Q27284539|(2R)-8-(4-(3-(5-FLUORO-1H-INDOL-3-YL)PROPYL)PIPERIDIN-1-YL)-2-METHYL-2H-1,4-BENZOXAZIN-3(4H)-ONE|(R)-8-{4-[3-(5-Fluoro-1H-indol-3-Show More⌵

Canonical SMILES:  C[C@H]1Oc2c(cccc2N2CCN(CCCc3c[nH]c4ccc(F)cc34)CC2)NC1=O

Standard InChI:  InChI=1S/C24H27FN4O2/c1-16-24(30)27-21-5-2-6-22(23(21)31-16)29-12-10-28(11-13-29)9-3-4-17-15-26-20-8-7-18(25)14-19(17)20/h2,5-8,14-16,26H,3-4,9-13H2,1H3,(H,27,30)/t16-/m1/s1

Standard InChI Key:  SDAMYSWGWHXMRT-MRXNPFEDSA-N

Alternative Forms

1. Parent:

   

   ALA196514

   Lensiprazine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 422.50

Molecular Weight (Monoisotopic): 422.2118

AlogP: 3.78

#Rotatable Bonds: 5

Polar Surface Area: 60.60

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.50

CX Basic pKa: 8.30

CX LogP: 3.98

CX LogD: 3.03

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.66

Np Likeness Score: -0.93

References

1. Smid P, Coolen HK, Keizer HG, van Hes R, de Moes JP, den Hartog AP, Stork B, Plekkenpol RH, Niemann LC, Stroomer CN, Tulp MT, van Stuivenberg HH, McCreary AC, Hesselink MB, Herremans AH, Kruse CG..  (2005)  Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[omega-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition.,  48  (22): [PMID:16250644] [10.1021/jm050148z]

2. Lange JH, Reinders JH, Tolboom JT, Glennon JC, Coolen HK, Kruse CG..  (2007)  Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.,  50  (21): [PMID:17880057] [10.1021/jm070516u]

Source

Source(1):

• Scientific Literature